208731 Sigma-AldrichCalpain Substrate II, Fluorogenic - CAS 94367-20-1 - Calbiochem
Cyclic fluorogenic substrate for the quantitative determination of calpain -1 and -2.
More>> Cyclic fluorogenic substrate for the quantitative determination of calpain -1 and -2. Less<<Synonyme: Suc-LY-AMC
Empfohlene Produkte
Übersicht
| Replacement Information |
|---|
Preis & Verfügbarkeit
| Bestellnummer | Verfügbarkeit | Verpackung | St./Pkg. | Preis | Menge | |
|---|---|---|---|---|---|---|
| 208731-25MG |
|
Kst.-Ampulle | 25 mg |
|
— |
| References | |
|---|---|
| References | Seol, J.H., et al. 1989. FEBS Lett. 247, 197. Woo, K.M., et al. 1989. J. Biol. Chem. 264, 2088. Sasaki, T., et al. 1984. J. Biol. Chem. 259, 12489. |
| Product Information | |
|---|---|
| CAS number | 94367-20-1 |
| ATP Competitive | N |
| Form | Off-white solid |
| Hill Formula | C₂₉H₃₁N₃O₇ |
| Chemical formula | C₂₉H₃₁N₃O₇ |
| Reversible | N |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | Calpain -1 and -2 |
| Purity | ≥95% by TLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | N |
| Emission max. | |
| Excitation max. | |
| Peptide Sequence | Suc-Leu-Tyr-AMC |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information |
|---|
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Bestellnummer | GTIN |
| 208731-25MG | 04055977202748 |
Documentation
Calpain Substrate II, Fluorogenic - CAS 94367-20-1 - Calbiochem SDB
| Titel |
|---|
Calpain Substrate II, Fluorogenic - CAS 94367-20-1 - Calbiochem Analysenzertifikate
| Titel | Chargennummer |
|---|---|
| 208731 |
Literatur
| Übersicht |
|---|
| Seol, J.H., et al. 1989. FEBS Lett. 247, 197. Woo, K.M., et al. 1989. J. Biol. Chem. 264, 2088. Sasaki, T., et al. 1984. J. Biol. Chem. 259, 12489. |



